MWVC
REGN icon

Morgens Waterfall Vintiadis & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,500
Closed -$1.08M – 39
2023
Q2 		$1.08M Buy
+1,500
New +$1.16M 0.77% 29

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's REGN Position: Q4 2024 in Review

Morgens Waterfall Vintiadis & Co sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 3,300 shares — an estimated $3.47M sold.

Morgens Waterfall Vintiadis & Co first reported a position in REGN in Q2 2021 and held it in 12 quarters. The position peaked at $3.75M in Q1 2024. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Morgens Waterfall Vintiadis & Co reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 3,300 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $3.47M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Morgens Waterfall Vintiadis & Co's Regeneron Pharmaceuticals position peaked at $3.75M in Q1 2024.
  • 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q4 2024, filed 14 Feb 2025.